Skip to main content

Table 3 Prognostic value of Bcl-2 expression estimated by multivariate analysis in the global cohort of 180 FMCs

From: Bcl-2 expression and prognostic significance in feline invasive mammary carcinomas: a retrospective observational study

  Categories p HR 95%-CI
Disease-free interval
 Bcl-2 expression Bcl-2+ versus Bcl-2– 0.034 0.57 0.34–0.96
 Pathologic tumor size pT ≥ 20 mm versus < 20 mm 0.029 1.52 1.04–2.21
 Pathologic nodal stage pNX versus pN0 0.109 1.71 0.89–3.28
pN+ versus pN0 0.007 2.36 1.27–4.41
Overall survival
 Bcl-2 expression Bcl-2+ versus Bcl-2– 0.015 0.58 0.37–0.90
 Pathologic tumor size pT ≥ 20 mm versus < 20 mm 0.002 1.64 1.20–2.25
 Pathologic nodal stage pNX versus pN0 0.252 1.38 0.80–2.36
pN+ versus pN0 0.003 2.15 1.30–3.55
 Distant metastasis MX versus M0 0.083 0.74 0.53–1.04
M1 versus M0 0.034 2.28 1.07–4.87
 Tumor-associated inflammation Absence to mild versus moderate to severe 0.034 0.71 0.51–0.97
Cancer-specific survival
 Bcl-2 expression Bcl-2+ versus Bcl-2– 0.008 0.50 0.30–0.84
 Pathologic tumor size pT ≥ 20 mm versus < 20 mm 0.002 1.78 1.24–2.55
 Pathologic nodal stage pNX versus pN0 0.296 1.42 0.74–2.75
pN+ versus pN0 0.002 2.63 1.44–4.80
 Distant metastasis MX versus M0 0.026 0.65 0.44–0.95
M1 versus M0 0.022 2.47 1.14–5.32